Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2007

01-08-2007 | Research Articles

Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription

Authors: V. Cepero, B. García-Serrelde, V. Moneo, F. Blanco, A. M. González-Vadillo, A. Álvarez-Valdés, C. Navarro-Ranninger, A. Carnero

Published in: Clinical and Translational Oncology | Issue 8/2007

Login to get access
Metadata
Title
Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription
Authors
V. Cepero
B. García-Serrelde
V. Moneo
F. Blanco
A. M. González-Vadillo
A. Álvarez-Valdés
C. Navarro-Ranninger
A. Carnero
Publication date
01-08-2007
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 8/2007
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-007-0096-2

Other articles of this Issue 8/2007

Clinical and Translational Oncology 8/2007 Go to the issue

Editorial

PET-CT in oncology

Case Reports

Pathological femur fracture secondary to radiation therapy for soft tissue sarcoma

Educational Series

Molecular biology of neuroblastoma

Case Reports

Heart metastases and superior vena cava syndrome

News and Views

The story of a fly

Reviews

Toxicity associated to radiotherapy treatment in lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits